Skip to main content
Home
Zeitschriften
Zeitungen
Podcast
Gesundheitspolitik
Praxis
Allerlei
Jobs
Fachgebiete
Allgemeinmedizin Anästhesiologie & Intensivmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kinder & Jugendheilkunde Neurologie & Psychiatrie Orthopädie & Unfallchirurgie Pflege Urologie Zahnmedizin Apotheke
Subfächer Innere Medizin
Diabetologie Gastroenterologie Infektiologie Kardiologie Onkologie und Hämatologie Pneumologie Rheumatologie
Fortbildungen
Überblick Fortbildungen DFP-Literaturstudium-Artikel DFP-Webcast Fortbildungen DFP-Podcasts
Erweiterte Suche
Anmelden
nach oben
memo - Magazine of European Medical Oncology
Erschienen in: memo - Magazine of European Medical Oncology 1/2015

01.04.2015 | short review

PET in lymphoma: who, when, how often, pitfalls?

verfasst von: Christian Uprimny, MD

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 1/2015

Einloggen, um Zugang zu erhalten

Abstract

For optimal therapy management in patients with lymphoma, sensitive and specific imaging modalities for accurate initial staging and evaluation of response to therapy are crucial. Fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) that combines metabolic information of 18F-FDG PET with morphological information of diagnostic CT has proven to be a very useful tool in the work-up of lymphomas. Especially in 18F-FDG-avid tumours like Hodgkin lymphoma and high-grade, aggressive non-Hodgkin lymphoma, 18F-FDG PET/CT is widely used for pre-treatment staging and response evaluation after completion of therapy with convincing evidence that it is more accurate than conventional imaging modalities. Although 18F-FDG PET/CT is also applied in other subtypes of lymphoma and in other clinical indications such as early response assessment, its benefit in these settings remains controversial. This review is intended to highlight the accepted clinical applications for 18F-FDG PET/CT in lymphoma, delivering a short clinical guideline when it is recommended to perform 18F-FDG PET/CT in a patient with lymphoma.
Vorheriger Artikel Clinical update: B-cell receptor kinase inhibitors in chronic lymphocytic leukemia
Nächster Artikel Beyond R-CHOP: treatment of double hit, tripple hit, MYC + NHL?
Literatur
1.
Rodriguez-Vigil B, Gomez-Leon N, Pinilla I, et al. PET/CT in lymphoma: prospective study of enhanced full-dose PET/CT versus unenhanced low-dose PET/CT. J Nucl Med. 2006;47(10):1643–8.PubMed
2.
Hutchings M, Loft A, Hansen M, et al. Positron emission tomography with or without computed tomography in the primary staging of Hodgkinʼs lymphoma. Haematologica. 2006;91:482–9.PubMed
3.
Schaefer NG, Hany TF, Taverna C, et al. Non-Hodgkin lymphoma and Hodgkin disease: coregistered FDG PET and CT at staging and restaging—do we need contrast-enhanced CT? Radiology. 2004;232:823–9.CrossRefPubMed
4.
Naumann R, Beuthien-Baumann B, Reiss A, et al. Substantial impact of FDG-PET imaging on the therapy decision in patients with early-stage Hodgkinʼs lymphoma. Br J Cancer. 2004;90(3):620–5.CrossRefPubMedCentralPubMed
5.
Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25(5):579–86.CrossRefPubMed
6.
Pelosi E, Pregno P, Penna D, et al. Role of whole body [18F] fluorodeoxyglucose positron emission tomography (FDG-PET/CT) and conventional techniques in the staging of patients with Hodgkin and aggressive non-Hodgkin lymphoma. Radiol Med. 2008;113(4):578–90.CrossRefPubMed
7.
Le Dortz L, De Guibert S, Bayat S, et al. Diagnostic and prognostic impact of (18F)F-FDG PET/CT in follicular lymphoma. Eur J Nucl Med Mol Imaging. 2010;37(12):2307–14.CrossRefPubMed
8.
Jerusalem G, Beguin Y, Najjar F, et al. Positron emission tomography (PET) with 18F-fluorodeoxyglucose (18F-FDG) for the staging of low-grade non-Hodgkinʼs lymphoma (NHL). Ann Oncol. 2001;12(6):825–30.CrossRefPubMed
9.
Bishu S, Quigley J.M., Schmitz J, et al. F-18-fluoro-deoxy-glucose (FDG) positron emission tomography (PET) in the assessment of peripheral T-cell lymphomas. Leuk Lymphoma. 2007;48(8):1531–8.CrossRefPubMed
10.
Kako S, Izutsu K, Ota Y, et al. FDG-PET in T-cell and NK-cell neoplasms. Ann Oncol. 2007;18(10):1685–90.CrossRefPubMed
11.
Hofmann M, Kletter K, Diemling M, et al. Positron emission tomography with fluorine-18-2-fluoro-2-deoxy-D-glucose (F18-FDG) does not visualize extranodal B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT)-type. Ann Oncol. 1999;10(10):1185–9.CrossRef
12.
Weiler-Sagie M, Bushelev O, Epelbaum R, et al. 18F-FDG avidity in lymphoma readdressed: a study of 766 patients. J Nucl Med. 2010;51(1):25–30.CrossRefPubMed
13.
Isasi CR, Lu P, Blaufox MD. A metaanalysis of 18F-2-deoxy-2-fluouro-D-glucose positron emission tomography in the staging and restaging of patients with lymphoma. Cancer. 2005;104(5):1066–74.CrossRefPubMed
14.
Sasaki M, Kuwabara Y, Koga H, et al. Clinical impact of whole body FDG-PET on the staging and therapeutic decision making for malignant lymphoma. Ann Nucl Med. 2002;16(5):337–45.CrossRefPubMed
15.
Schoeder H, Meta J, Yap C, et al. Effect of whole body (18)F-FDG PET imaging on clinical staging and management of patients with malignant lymphoma. J Nucl Med. 2001;42(8):1139–43.
16.
Naumann R, Beuthien-Baumann B, Reiss A, et al. Substantial impact of FDG PET imaging on the therapy decision in patients with early-stage Hodgkinʼs lymphoma. Br J Cancer. 2004;90(9):620–5.CrossRefPubMedCentralPubMed
17.
Cheng G, Chen W, Chamroonraat W, et al. Biopsy versus FDG PET/CT in the initial evaluation of bone marrow involvement in pediatric lymphoma patients. Eur J Nucl Med Mol Imaging. 2011;38(8):1469–76.CrossRefPubMed
18.
Schaefer NG, Strobel K, Taverna C, et al. Bone involvement in patients with lymphoma: the role of FDG-PET/CT. Eur J Nucl Med Mol Imaging. 2007;34(1):60–7.CrossRefPubMed
19.
El-Galaly TC, dʼAmore F, Mylam KJ, et al. Routine bone marrow biopsy has little or no therapeutic consequence for positron emission tomography/computed tomography-staged treatment-naive patients with Hodgkin lymphoma. J Clin Oncol. 2012;30(36):4508–14.CrossRefPubMed
20.
Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014 Aug 11. Epub ahead of print.
21.
Von Treskow B, Plütschow A, Fuchs A, et al. Dose-intensification in early unfavorable Hodgkinʼs lymphoma: final analysis of the German Hodgkin Study Group HD14 trial. J Clin Oncol. 2012;30(9):907–13.CrossRef
22.
Dunleavy K, Mikhaeel G, Sehn LH, et al. The value of positron emission tomography in prognosis and response assessment in non-Hodgkin lymphoma. Leuk Lymphoma. 2010;51(Suppl. 1):28–33.CrossRefPubMed
23.
Terasawa T, Lau J, Bardet S, et al. Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkinʼs lymphoma and diffuse large B-cell lymphoma: a systematic review. J Clin Oncol. 2009;27(11):1906–14.CrossRefPubMed
24.
Gallamini A, Rigacci L, Merli F, et al. The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkinʼs disease. Haematologica. 2006;91(4):475–81.PubMed
25.
Cerci JJ, Pracchia LF, Linardi CC, et al. 18F-FDG PET after 2 cycles of ABVD predicts event-free survival in early and advanced Hodgkin lymphoma. J Nucl Med. 2010;51(9):1337–43.CrossRefPubMed
26.
Moskowitz AJ, Yahalom J, Zelenetz AD, et al. High-dose chemo-radiotherapy for relapsed or refractory Hodgkin lymphoma and the significance of pre-transplant functional imaging. Br J Haematol. 2010;148(6):890–7.CrossRefPubMedCentralPubMed
27.
Juweid ME, Stroobants S, Hoekstra OS, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol. 2007;25(5):571–8.CrossRefPubMed
28.
Juweid ME. 18F-FDG PET as a routine test for post therapy assessment of Hodgkinʼs lymphoma: where is the evidence. J Nucl Med. 2008;49(1):9–12.CrossRefPubMed
29.
Zijlstra JM, Linduer-van der Werf G, Hoekstra OS, et al. 18F-fluoro-deoxyglucose positron emission tomography for post-treatment evaluation of malignant lymphoma: a systemic review. Haematologica. 2006;91(4):522–9.PubMed
30.
Naumann R, Vaic A, Beuthien-Baumann B, et al. Prognostic value of positron emission tomography in the evaluation of post-treatment residual mass in patients with Hodgkinʼs disease and non-Hodgkinʼs lymphoma. Br J Haematol. 2001;115(4):793–800.CrossRefPubMed
31.
Zinzani PL, Stefoni V, Tani M, et al. Role of [18F]fluorodeoxyglucose positron emission tomography scan in the follow-up of lymphoma. J Clin Oncol. 2009;27(11):1781–7.CrossRefPubMed
32.
Crocchiolo R, Fallanca F, Giovacchini G, et al. Role of 18FDG-PET/CT in detecting relapse during follow-up of patients with lymphoma. Ann Hematol. 2009;88(12):1229–36.CrossRefPubMed
Metadaten
Titel
PET in lymphoma: who, when, how often, pitfalls?
verfasst von
Christian Uprimny, MD
Publikationsdatum
01.04.2015
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 1/2015
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-014-0175-3

Weitere Artikel der Ausgabe 1/2015

memo - Magazine of European Medical Oncology 1/2015 Zur Ausgabe

case report

High-dose chemotherapy and autologous hematopoietic stem cell transplantation in a myeloma patient with terminal renal failure and hepatitis C with high viral load

short review

Optimal follow-up of cervical cancer patients

short review

Optimal follow-up of endometrial cancer patients

short review

Clinical update: B-cell receptor kinase inhibitors in chronic lymphocytic leukemia

editorial

Lymphoma: anything new?

short review

Tailoring treatment in myeloma: are there clues from biology?